Login to Your Account

Pharma: Other News To Note

Friday, May 31, 2013

• Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA accepted for review the company's supplemental new drug application for Copaxone (glatiramer acetate injection) 40 mg/1mL, a higher concentration dose designed to offer a less frequent three-times-per-week dosing schedule for patients with relapsing-remitting multiple sclerosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription